清热解毒方联合洛铂介入栓塞治疗原发性肝癌临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.7

基金项目:


Clinical Study on Qingre Jiedu Prescription Combined with Interventional Embolization with Lobaplatin for Primary Liver Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察清热解毒方联合洛铂介入栓塞治疗原发性肝癌的临床疗效。方法:将110 例原发性肝癌患者随机分为观察组与对照组各55 例。对照组实施洛铂介入栓塞化疗,观察组在对照组的基础上给予清热解毒方治疗,均以30 d 为1 个疗程,共治疗3 个疗程。观察2 组临床疗效,记录治疗前后血清总胆红素(TBil)、谷氨酸转氨酶(ALT)、天门冬氨酸氨基转移酶(AST) 含量及癌症治疗功能评价-普适性量表(FACT-G) 评分,统计治疗期间化疗药物毒性反应情况。结果:观察组总有效率为45.45%,对照组为25.45%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组血清TBil、ALT、AST 水平比较,差异无统计学意义(P>0.05);治疗后,2 组血清TBil、ALT、AST 水平均较治疗前降低(P<0.05),且观察组TBil、ALT、AST 水平均低于对照组(P<0.05)。治疗前,2 组FACT-G 量表各维度评分比较,差异无统计学意义(P>0.05)。治疗前,2 组FACT-G量表各维度评分比较,差异无统计学意义(P>0.05)。治疗后,观察组FACT-G 量表各项评分较治疗前变化不大(P>0.05),但各项评分均高于对照组(P<0.05);对照组FACT-G 量表中躯体维度评分低于治疗前(P<0.05),其余各项评分变化不大(P>0.05)。观察组上消化道反应、白细胞及血小板计数的毒性反应分级疗效均优于对照组(P<0.05)。结论:应用洛铂介入栓塞联合清热解毒方治疗原发性肝癌能充分发挥中西医结合治疗优势,改善肝功能,提高患者生活质量,有效降低化疗药物的不良反应。

    Abstract:

    Objective: To observe the clinical effect of Qingre Jiedu prescription combined with interventional chemoembolization with lobaplatin for primary liver cancer. Methods:A total of 110 cases of patients with primary liver cancer were randomly divided into the observation group and the control group,55 cases in each group. The control group was given interventional chemoembolization with lobaplatin,and the observation group was additionally given Qingre Jiedu prescription based on the treatment of the control group. Both groups were treated for three courses,30 days being a course. The clinical effect was observed in the two groups. Before and after treatment, score of Functional Assessment of Cancer Therapy- General(FACT-G) as well as contents of total bilirubin(TBil),alanine aminotransferase(ALT),and aspartate aminotransferase (AST) in serum was recorded. During treatment, toxic reactions caused by chemotherapeutic medicines were carried out statistical analysis. Results:The total effective rate was 45.45% in the observation group,and 25.45% in the control group, the difference being significant(P<0.05). Before treatment,when compared levels of TBil,ALT,and AST in serum between the two groups,there was no significance being found in the difference(P>0.05). After treatment,levels of TBil,ALT,and AST in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the three levels in the observation group were lower than those in the control group(P<0.05). Before treatment,when compared scores of all dimensions in FACT- G between the two groups, there was no significance being found in the difference(P>0.05). After treatment,the scores of FACT-G scale in the observation group had little change compared with those before treatment(P> 0.05), but they were higher than those in the control group(P<0.05).The body dimension score of FACT- G scale in the control group was lower than that before treatment(P<0.05), and the other scores had little change(P>0.05). In the observation group,the curative effect of grading of toxic reactions including upper gastrointestinal reaction,white blood cell count, and platelet count was better than that in the control group(P<0.05). Conclusion: For patients with primary liver cancer,the therapy of Qingre Jiedu prescription combined with interventional chemoembolization with lobaplatin can give full play to treatment advantages of integrated Chinese and western medicine therapy, improve the liver function, promote quality of life,and effectively relieve adverse reactions caused by chemotherapeutic medicines.

    参考文献
    相似文献
    引证文献
引用本文

琚洁,陈倚天.清热解毒方联合洛铂介入栓塞治疗原发性肝癌临床研究[J].新中医,2021,53(13):122-126

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-07-11
  • 出版日期: